NCLEX Oncology Review: Neutropenia, Chemo Safety, and Emergencies

Quick answer: NCLEX oncology questions test safety: an ANC below 500 requires neutropenic precautions, and a temperature of 100.4°F (38°C) or higher in a neutropenic patient needs blood cultures and broad-spectrum antibiotics within one hour. Stop a vesicant infusion if extravasation is suspected, recognize tumor lysis labs (high potassium, phosphorus, and uric acid; low calcium), treat new back pain in cancer as cord compression, and apply time, distance, and shielding to radioactive patients.

Oncology questions on the NCLEX test whether you can keep a chemotherapy patient safe. Neutropenia, extravasation, tumor lysis, spinal cord compression, radiation safety – these are the scenarios that separate nurses who can manage an oncology patient from those who cannot. This review covers chemotherapy safety, oncologic emergencies, common cancers, and the radiation precautions you will see on test day.

Key takeaways

• Neutropenia is the immediate threat. An ANC below 500 mandates neutropenic precautions, and a fever of 100.4°F (38°C) in a neutropenic patient is an emergency requiring blood cultures and broad-spectrum antibiotics within one hour.
• Extravasation has a fixed step sequence. Stop the infusion, leave the catheter in, aspirate residual drug, do not flush, notify provider and pharmacy, and give the drug-specific antidote.
• Tumor lysis syndrome shows a classic lab pattern. Hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia after starting chemo – treat with aggressive hydration and urate-lowering therapy.
• New back pain in a cancer patient is spinal cord compression until proven otherwise. It is a neurologic emergency requiring emergent MRI and high-dose IV dexamethasone.
• Radiation safety follows time, distance, and shielding. External beam patients are not radioactive; brachytherapy and unsealed isotope patients are, so minimize time, maximize distance, and use shielding.
• Tumor markers drive treatment. ER/PR and HER2 status guide breast cancer therapy, and recognizing the right marker is frequently tested.

Chemotherapy and neutropenia

Most chemotherapy agents kill rapidly dividing cells, which means cancer cells and also hair follicles, GI mucosa, and bone marrow. Bone marrow suppression is the dose-limiting toxicity for most regimens, and neutropenia is what will kill the patient before the cancer does.

Understanding the ANC

Absolute neutrophil count (ANC) determines infection risk.

• ANC greater than 1500: normal
• ANC 1000-1500: mild neutropenia – low risk
• ANC 500-1000: moderate neutropenia – moderate risk
• ANC less than 500: severe neutropenia – neutropenic precautions required
• ANC less than 100: profound neutropenia – extreme risk of fatal infection

Chemotherapy nadir (lowest blood counts) typically occurs 7-14 days after treatment. Know when your patient’s nadir is expected and ramp up monitoring and precautions during that window.

Neutropenic precautions

The patient cannot mount an inflammatory response, so signs of infection will be blunted. A fever of 100.4°F (38°C) in a neutropenic patient is a medical emergency – neutropenic fever – and requires blood cultures and broad-spectrum antibiotics within one hour.

• Private room with HEPA filtration if available
• Strict handwashing by all staff and visitors before and after contact
• No sick visitors and no live plants or fresh flowers (water and soil harbor gram-negative bacteria and fungi like Aspergillus)
• No fresh fruits or raw vegetables unless peeled (bacterial contamination). Some protocols allow fresh produce if thoroughly washed and peeled; follow facility policy. Cooked foods only in strict protocols.
• No live vaccines (MMR, varicella, live intranasal influenza, rotavirus). Household contacts should still receive MMR, varicella, and rotavirus vaccines when indicated (CDC); a contact who develops a rash after varicella vaccine should avoid direct contact with the patient until it resolves, and contacts should not receive the live nasal flu vaccine if the patient is in a protective environment.
• Avoid crowds, construction zones, sick people, and invasive procedures when possible
• Meticulous oral care with soft toothbrush and non-alcohol rinse – mucositis provides bacterial entry
• No rectal temperatures, suppositories, or enemas – rectal mucosa disruption can seed bloodstream infection
• Daily CBC with differential to trend counts
• Filgrastim (Neupogen) or pegfilgrastim (Neulasta): granulocyte colony-stimulating factors used to shorten neutropenia. Side effect: bone pain from marrow expansion.

Chemotherapy safety: handling and extravasation

Safe handling

Chemotherapy drugs are hazardous to the patient, the nurse, and anyone who handles body fluids. USP 800 standards govern handling.

• PPE: chemotherapy-rated gown, double gloves, eye protection, respirator for aerosol-generating tasks
• Mix in biological safety cabinet or compounding isolator – not at the bedside
• Patient body fluids (urine, stool, emesis, blood) are considered hazardous for 48 hours after administration – wear PPE when handling
• Spill kits and chemotherapy-specific waste containers must be available
• Pregnant nurses and those trying to conceive should follow facility policy – many facilities restrict chemo handling

Extravasation

Vesicant chemotherapy (doxorubicin, vincristine, vinblastine, mitomycin, mechlorethamine) causes severe tissue necrosis if it leaks from the vein. Prevention: central venous access for known vesicants, frequent infusion site assessment, good IV technique.

If extravasation is suspected (pain, burning, redness, swelling, lack of blood return):

1. Stop the infusion immediately – do not continue the administration
2. Disconnect the tubing but leave the IV catheter in place
3. Aspirate any residual drug from the catheter with a syringe
4. Do not flush the catheter with saline – that pushes more drug into the tissue
5. Notify the provider and the oncology pharmacist immediately
6. Give the antidote if indicated (dexrazoxane for anthracyclines like doxorubicin; hyaluronidase for vinca alkaloids; sodium thiosulfate for mechlorethamine)
7. Apply cold or warm compress based on drug – cold for anthracyclines, warm for vinca alkaloids and taxanes. Cold goes on as soon as the extravasation is recognized; if dexrazoxane is being given for an anthracycline, the cold compress comes off at least 15 minutes before the infusion and is not reapplied during it (cold vasoconstricts and impedes drug diffusion). Follow protocol.
8. Elevate the extremity to reduce swelling
9. Document: drug, volume infused, time, appearance, interventions, patient symptoms, photograph per policy
10. Outline the area with a skin marker and note time – monitor for progression

Oncologic emergencies

These are the can-kill-the-patient-today diagnoses. Recognize them fast.

Tumor lysis syndrome (TLS)

Massive cell lysis (usually after starting chemo for high-cell-burden cancers like acute leukemia, Burkitt lymphoma, or aggressive lymphomas) dumps intracellular contents into the bloodstream.

Classic lab findings:

• Hyperuricemia (uric acid from nucleic acid breakdown)
• Hyperkalemia (potassium from cell lysis)
• Hyperphosphatemia (phosphate from cells)
• Hypocalcemia (calcium binds to phosphate and precipitates)

Consequences: acute kidney injury (uric acid and calcium phosphate crystals obstruct tubules), cardiac dysrhythmias (hyperkalemia), tetany and seizures (hypocalcemia).

Prevention and treatment:

• Aggressive hydration – often 2-3 times maintenance fluid, with goal urine output greater than 100 mL/hr, started 24-48 hours before chemotherapy in high-risk patients. Specialty TLS guidelines set this urine output goal per body surface area instead, at 80-100 mL/m2/hr – a somewhat higher bar that works out to about 140-170 mL/hr at a typical 1.7 m2 body surface area. Greater than 100 mL/hr is the commonly taught figure and the one to use on the exam.
• Allopurinol (xanthine oxidase inhibitor) – prophylaxis for moderate-risk patients. Blocks uric acid formation.
• Rasburicase (recombinant urate oxidase) – converts existing uric acid to allantoin. Used for high-risk or established TLS. Contraindicated in G6PD deficiency.
• Monitor electrolytes every 4-6 hours during initial chemotherapy for high-risk patients
• Treat hyperkalemia urgently (calcium gluconate, insulin/dextrose, dialysis if refractory)
• Dialysis for renal failure, severe hyperkalemia, or severe hyperphosphatemia unresponsive to medical management

Superior vena cava syndrome (SVC syndrome)

Tumor (often lung cancer, lymphoma, or metastatic disease) compresses the SVC, obstructing venous return from the head, neck, and upper extremities.

• Signs: facial and upper extremity edema, distended neck and chest veins, cyanosis of face and upper body, dyspnea, cough, headache (from venous congestion), positive Pemberton’s sign (face flushes when arms raised above head)
• Nursing: elevate HOB to promote drainage, avoid upper extremity IVs (they will not drain), monitor airway and breathing, oxygen
• Treatment: radiation therapy, chemotherapy, or stenting depending on tumor type. Steroids may be used. Anticoagulation if thrombosis is present.

Spinal cord compression

Metastatic disease (common in breast, lung, prostate, multiple myeloma) compresses the cord or cauda equina. This is a neurologic emergency. Delayed recognition causes permanent paralysis.

• Signs: new or worsening back pain (often the earliest symptom), radicular pain, motor weakness below the level, sensory changes, bowel or bladder dysfunction (late and ominous)
• Action: emergent MRI to localize, high-dose IV dexamethasone to reduce cord edema, urgent radiation oncology or neurosurgery consult
• Nursing: maintain spinal alignment, minimize movement until stabilized, pain management, bowel and bladder care, fall precautions, pressure injury prevention if immobile
• New back pain in a cancer patient is spinal cord compression until proven otherwise – escalate quickly

Hypercalcemia of malignancy

Bone metastases or paraneoplastic PTH-related peptide raise serum calcium. Common in breast, lung, multiple myeloma, and squamous cell cancers.

• Signs: “stones, bones, groans, psychiatric overtones” – kidney stones, bone pain, abdominal pain (constipation, nausea, ileus), altered mental status; also polyuria, polydipsia, dehydration, shortened QT, cardiac dysrhythmias
• Treatment: aggressive IV isotonic fluids (normal saline) to dilute calcium and enhance renal excretion, loop diuretics (furosemide) only after the patient is fully volume-repleted, to promote calciuresis (current oncology guidance reserves loops for patients with renal insufficiency or heart failure at risk of fluid overload rather than routine use) – never use thiazides (they retain calcium), bisphosphonates (zoledronic acid, pamidronate) to inhibit osteoclast activity, calcitonin for rapid short-term effect, denosumab, dialysis for severe refractory cases
• Nursing: cardiac monitoring, safety precautions for altered mental status, fall prevention (weak muscles, confusion), strict I/O

Common cancers on the NCLEX

Breast cancer

• Screening: USPSTF (2024) recommends biennial mammography starting at age 40; ACS recommends annual screening starting at 45 (optional from 40). High-risk patients may need MRI and BRCA testing.
• Biopsy confirms diagnosis; staging determines treatment
• Tumor markers that drive therapy:
  • ER/PR positive: responsive to hormonal therapy (tamoxifen in premenopausal; aromatase inhibitors like anastrozole, letrozole, exemestane in postmenopausal)
  • HER2 positive: treated with trastuzumab (Herceptin) – monitor cardiac function before and during therapy; can cause cardiomyopathy
  • Triple negative (ER/PR/HER2 negative): chemotherapy-dependent; more aggressive
• Post-mastectomy arm: no BP, no IV, no venipuncture, no injections, no tight jewelry on affected side (lymphedema risk). Teach arm ROM and elevation.
• Tamoxifen risks: DVT/PE, endometrial cancer, hot flashes

Prostate cancer

• Screening: PSA-based screening in men 55-69 is an individual, shared decision-making choice (USPSTF grade C). USPSTF does not recommend digital rectal exam as a screening modality, though DRE is still commonly taught and performed alongside PSA. Earlier screening for high-risk patients (Black men, family history)
• PSA elevation is not specific – BPH, prostatitis, and recent ejaculation or DRE also raise it
• Treatment: active surveillance for low-risk, radical prostatectomy, radiation (external beam or brachytherapy), androgen deprivation therapy (leuprolide, goserelin), chemotherapy for advanced disease
• Post-prostatectomy: urinary incontinence and erectile dysfunction are common – pelvic floor exercises (Kegels) help

Colorectal cancer

• Screening starts at age 45 (per ACS updated guidance) for average risk: colonoscopy every 10 years, or stool-based tests (FIT annually, stool DNA every 3 years)
• Earlier screening for family history, inflammatory bowel disease, or Lynch syndrome
• Signs: change in bowel habits, rectal bleeding, unexplained weight loss, iron deficiency anemia in older adults
• Treatment: surgical resection, chemotherapy (FOLFOX, capecitabine), radiation for rectal cancer
• Ostomy care teaching if colostomy created

Lung cancer

• Leading cause of cancer death. Smoking is the dominant risk factor.
• Small cell lung cancer (SCLC): aggressive, rapidly metastasizing, strongly linked to smoking. Treated primarily with chemotherapy and radiation; rarely surgical candidates at diagnosis. Often presents with paraneoplastic syndromes (SIADH, Cushing’s, Lambert-Eaton).
• Non-small cell lung cancer (NSCLC): 85% of lung cancers. Adenocarcinoma, squamous cell, large cell. Earlier-stage disease can be surgically resected. Targeted therapy for EGFR, ALK, ROS1, and other molecular markers; immunotherapy (pembrolizumab, nivolumab) for PD-L1 positive tumors.
• Screening: low-dose CT annually for adults 50-80 with 20 pack-year smoking history who currently smoke or quit within 15 years (USPSTF)
• Common symptoms: chronic cough, hemoptysis, weight loss, chest pain, dyspnea

Radiation therapy safety

External beam radiation

The patient is not radioactive. Staff and family are safe to be near them.

• Do not wash off the radiation markings – they guide treatment
• Skin care: gentle cleansing with mild soap, pat dry, no perfumes, deodorants with metallic salts, or lotions in the treatment field unless approved
• Protect from sun exposure – covered clothing, SPF 30+ after treatment completes
• Fatigue is common – schedule rest periods
• Site-specific side effects: head/neck radiation causes mucositis and xerostomia; pelvic radiation causes cystitis and diarrhea; chest radiation risks pneumonitis and esophagitis

Internal radiation (brachytherapy / sealed source implants)

The patient is emitting radiation while the source is in place. Three principles govern safety:

1. Time: Minimize time in the room. Cluster care. Plan tasks in advance.
2. Distance: Dose falls with the square of the distance (inverse square law) – doubling your distance cuts exposure to one-quarter. Stand at the foot of the bed rather than the head when possible. For cervical implants, stand at least 6 feet away except during direct care.
3. Shielding: Lead shields for direct contact tasks. Dosimetry badge for all staff entering the room.

Internal radiation room rules:

• Private room with a radiation sign on the door
• Pregnant staff and children do not enter
• Visitors limited to 30 minutes per day at a distance of 6 feet – no pregnant visitors or children
• Lead-lined container in the room at all times in case the implant dislodges – use long-handled forceps (never hands) to return a dislodged source to the container and notify radiation safety immediately
• Check linens and bedpan contents before discarding to ensure the implant has not dislodged
• After removal, the patient and room are not radioactive and precautions are lifted

Unsealed radioactive isotopes (oral or IV)

Used for thyroid cancer (I-131), bone metastases (strontium-89, radium-223). Body fluids are radioactive for several days. Precautions include:

• Private room, private bathroom
• Flush toilet multiple times after use
• Separate laundry and dishes
• Distance from family members for a specified period (provider-directed)
• Avoid close contact with children and pregnant women for the recommended duration

Putting oncology together

Oncology questions cluster around three themes: protect the immunocompromised patient (neutropenic precautions), recognize the emergency (TLS, SCC, SVC, hypercalcemia), and respect the radioactivity (time, distance, shielding). Chemo extravasation has a specific step sequence you need to know. Tumor markers drive treatment decisions. If you can answer “what will hurt this patient in the next 24 hours?” you can pass oncology on the NCLEX.

For the chemotherapy drugs and related supportive agents (allopurinol, rasburicase, filgrastim, ondansetron), see our pharmacology review. For labs you will be trending daily (ANC, electrolytes, renal function, tumor markers), see the lab values guide. For how oncology scenarios appear in NGN case studies, see the NGN question types guide.

Frequently Asked Questions

What ANC means a patient needs neutropenic precautions?

An absolute neutrophil count below 500 is severe neutropenia and requires full neutropenic precautions. Below 100 is profound neutropenia with an extreme risk of fatal infection. Remember that the chemotherapy nadir, when counts are lowest, usually falls 7 to 14 days after treatment, so monitoring and precautions should ramp up during that window.

Why is a low-grade fever an emergency in a neutropenic patient?

A neutropenic patient cannot mount a normal inflammatory response, so the usual signs of infection are blunted and a single low-grade fever may be the only warning. A temperature of 100.4°F (38°C) is treated as neutropenic fever, an oncologic emergency that requires blood cultures and broad-spectrum antibiotics within one hour. Do not wait for the fever to climb or for other symptoms to appear.

What is the first step if chemotherapy extravasation is suspected?

Stop the infusion immediately. Then disconnect the tubing but leave the catheter in place, aspirate any residual drug, and do not flush the line because flushing pushes more drug into the tissue. Notify the provider and oncology pharmacist, give the drug-specific antidote if indicated, and apply the correct compress – cold for anthracyclines, warm for vinca alkaloids and taxanes.

How do you recognize tumor lysis syndrome on labs?

Look for the classic pattern that appears after chemotherapy starts for a high-cell-burden cancer: high uric acid, high potassium, high phosphorus, and low calcium, often with a rising creatinine and falling urine output. The priority is aggressive IV hydration plus urate-lowering therapy such as allopurinol for prevention or rasburicase for high-risk or established disease. Avoid giving IV calcium for the low calcium unless the patient is symptomatic, because it can worsen calcium phosphate crystal formation.

Which radiation patients are actually radioactive?

Patients receiving external beam radiation are not radioactive, so staff and family are safe to be near them. Patients with a sealed brachytherapy implant or who received unsealed radioactive isotopes such as I-131 are emitting radiation, so you apply the principles of time, distance, and shielding. Minimize time in the room, maximize distance, use lead shielding, and wear a dosimetry badge.